How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Primmune Therapeutics to Present PRTX007 Phase 1 Pharmacology and Phase 2 INFLECTION-003 Study Design at the SITC 41st Annual Meeting

calendar_today November 3, 2026 person admin domain primmune-therapeutics

SAN DIEGO, November 3, 2026 – Primmune Therapeutics, a clinical-stage biotech company harnessing the power of the innate and adaptive immune systems, today announced that two abstracts on polvitolimod HCl (also known as PRTX007), a novel orally administered, systemically acting toll-like receptor 7 (TLR7) agonist, will be presented at the Society for Immunotherapy of Cancer […] The post Primmune Therapeutics to Present PRTX007 Phase 1 Pharmacology and Phase 2 INFLECTION-003 Study Design at the SITC 41st Annual Meeting appeared first on Primmune .

open_in_new Read original post